Current approaches to management of high‐risk multiple myeloma

The median overall survival in multiple myeloma is rapidly approaching 10 years; however, nearly a fifth of patients the prognosis remains poor. Therefore, modern-day management should be individualized, with more intense and continuous approach these high-risk patients. This includes first-line treatment based on multi-drug combinations employing most effective drug combinations, upfront autologous stem cell transplantation (in eligible tandem being consideration), maintenance proteasome inhibitor-based combinations. paper reviews results recent retrospective analyses clinical trials, but also gives glance into future by presenting ongoing trials.